Cyclophosphamide and Hypertrichosis aggravated - a phase IV clinical study of FDA data


Hypertrichosis aggravated is found among people who take Cyclophosphamide, especially for people who are female, 2-9 old.

The phase IV clinical study analyzes which people take Cyclophosphamide and have Hypertrichosis aggravated. It is created by eHealthMe based on reports of 149,447 people who have side effects when taking Cyclophosphamide from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 03, 2022

149,447 people reported to have side effects when taking Cyclophosphamide.
Among them, 26 people (0.02%) have Hypertrichosis aggravated.

What is Cyclophosphamide?

Cyclophosphamide has active ingredients of cyclophosphamide. It is often used in multiple myeloma. eHealthMe is studying from 149,590 Cyclophosphamide users for its effectiveness, alternative drugs and more.

What is Hypertrichosis aggravated?

Hypertrichosis aggravated (hair growth on the body in an amount considered abnormal) is found to be associated with 452 drugs and 156 conditions by eHealthMe.

Number of Cyclophosphamide and Hypertrichosis aggravated reports submitted per year:

Could Cyclophosphamide cause Hypertrichosis aggravated?

Gender of people who have Hypertrichosis aggravated when taking Cyclophosphamide *:

  • female: 52.17 %
  • male: 47.83 %

Age of people who have Hypertrichosis aggravated when taking Cyclophosphamide *:

  • 0-1: 0.0 %
  • 2-9: 72.22 %
  • 10-19: 16.67 %
  • 20-29: 0.0 %
  • 30-39: 5.56 %
  • 40-49: 5.56 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Common drugs people take besides Cyclophosphamide *:

  1. Cyclosporine: 11 people, 42.31%
  2. Mycophenolate Mofetil: 9 people, 34.62%
  3. Prednisolone: 7 people, 26.92%
  4. Ciclosporin: 7 people, 26.92%
  5. Prednisone: 5 people, 19.23%
  6. Azathioprine: 3 people, 11.54%
  7. Tacrolimus: 2 people, 7.69%
  8. Methylprednisolone: 2 people, 7.69%
  9. Methotrexate: 2 people, 7.69%
  10. Zenapax: 2 people, 7.69%

Common side effects people have besides Hypertrichosis aggravated *:

  1. Osteoporosis (bones weak and more likely to break): 7 people, 26.92%
  2. Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 7 people, 26.92%
  3. High Blood Pressure: 7 people, 26.92%
  4. Cushing's Syndrome (obesity, a rounded face, increased fat): 7 people, 26.92%
  5. Breast Cancer: 7 people, 26.92%
  6. Herpes Zoster: 7 people, 26.92%
  7. Urinary Tract Infection: 6 people, 23.08%
  8. Infertility: 6 people, 23.08%
  9. Paronychia (infection in the tissues adjacent to a nail on a finger or toe): 6 people, 23.08%
  10. Gingival Hypertrophy (overgrowth of gums): 6 people, 23.08%

Common conditions people have *:

  1. Nephrotic Syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema): 8 people, 30.77%
  2. Immunodeficiency Disorders: 5 people, 19.23%
  3. Wegener's Granulomatosis (inflammation of the blood vessels lungs sinuses): 4 people, 15.38%
  4. Focal Segmental Glomerulosclerosis (scar tissue that forms in parts of the kidney called glomeruli): 2 people, 7.69%
  5. B Precursor Type Acute Leukaemia (lymphoid cancer): 2 people, 7.69%
  6. Vasculitis (inflammation of a blood vessel or blood vessels): 1 person, 3.85%
  7. Pemphigus (any of several acute or chronic skin diseases characterized by groups of itching blisters): 1 person, 3.85%
  8. Nephritic Syndrome (a collection of signs (known as a syndrome) associated with disorders affecting the kidneys, more specifically glomerular disorders): 1 person, 3.85%
  9. Langerhans' Cell Histiocytosis: 1 person, 3.85%
  10. Hypereosinophilic Syndrome (group of disorders marked by the sustained overproduction of eosinophiles): 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Cyclophosphamide and have Hypertrichosis aggravated?

Check whether Hypertrichosis aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

How severe was Hypertrichosis aggravated and when was it recovered:

Expand to all the drugs that have ingredients of cyclophosphamide:

Alternative drugs to, pros and cons of Cyclophosphamide:

Common Cyclophosphamide side effects:

Browse all side effects of Cyclophosphamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hypertrichosis aggravated treatments and more:

COVID vaccines that are related to Hypertrichosis aggravated:

Common drugs associated with Hypertrichosis aggravated:

All the drugs that are associated with Hypertrichosis aggravated:

Common conditions associated with Hypertrichosis aggravated:

All the conditions that are associated with Hypertrichosis aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on cyclophosphamide (the active ingredients of Cyclophosphamide) and Cyclophosphamide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: